Kinemed updates translational biomarkers strategy at 2010 Conference in Boston

Oct 21 2010

Marc K. Hellerstein, M.D., Ph.D. Co-Founder and Chief of SAB, Kinemed, Inc. presented an "Updated Strategy for Using Disease Predictive Translational Biomarkers in the Rapidly Advancing Field of Causal Pathway Measurements" at the 2010 Personalized and Translational Medicine Conference. In Boston, on September 20-21, 2010. To download the audio-visual presentation go to www.kinemed.com/index/presentation.

“Updated Strategy for Using Disease Predictive Translational Biomarkers in the Rapidly Advancing Field of Causal Pathway Measurements”

Dr. Hellerstein addressed the industry's leading problem in contemporary drug development − drug attrition. The problem of attrition is principally due to the unpredictability of complex biological networks. Kinemed addresses the problem through the use of its proprietary causal pathway biomarkers to provide real-time metrics of disease activity. Causal pathway biomarkers predict therapeutic activity, efficacy and toxicity essential in navigating drugs in development toward desired therapeutic outcomes.

The activities of many pathways that are pathogenic driving forces for common diseases (causal pathways) are now being measured by Kinemed in vivo, based on a detailed understanding of the underlying physiology and advances in mass spectrometric technology. These causal pathways drive the initiation, progression, severity and therapeutic reversal of disease and are closely linked to clinical outcomes, and in fact are predictive.

By characterizing a comprehensive set of measurable processes that capture diverse pathogenic aspects of complex diseases, a real-time systems view of complex disease activity can be generated. Unlike informatic approaches, which are based on establishing correlations, Kinemed interrogates causative events that have a priori functional significance in disease and treatment thus, serving to greatly improve decision making.

Kinemed's biomarkers have been validated in both animal models and clinical trials in multiple therapeutic areas including metabolic, neurodegenerative, fibrotic, inflammatory and hyper-proliferative disease. Kinemed continues to collaborate with pharmaceutical partners to advance their drug programs and to develop a proprietary pipeline of drugs validated with translational technologies.